BR9801157A - Derivados de adamantano substituìdos por flúor. - Google Patents

Derivados de adamantano substituìdos por flúor.

Info

Publication number
BR9801157A
BR9801157A BR9801157A BR9801157A BR9801157A BR 9801157 A BR9801157 A BR 9801157A BR 9801157 A BR9801157 A BR 9801157A BR 9801157 A BR9801157 A BR 9801157A BR 9801157 A BR9801157 A BR 9801157A
Authority
BR
Brazil
Prior art keywords
adamantane
relates
fluorine
formula
adamantane derivatives
Prior art date
Application number
BR9801157A
Other languages
English (en)
Inventor
Vytautus John Jasys
Robert Alfred Volkmann
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR9801157A publication Critical patent/BR9801157A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/38—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/15—Saturated compounds containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Patente de Invenção: <B>"DERIVADOS DE ADAMANTANO SUBSTITUìDOS POR FLúOR"<D>. A invenção refere-se a derivados de adamantano substituídos por flúor da fórmula e aos sais farmaceuticamente aceitáveis dos mesmos, em que R^ 1^, R^ 2^, R^ 3^ e R^ 4^ são conforme aqui definidos. A invenção também refere-ss, tais como perda de memória e doença de Parkinson, e infecções bacterianas e virais, através da ad refere-se a um método de aumentar a estabilidade metabólica de um composto farmacêutico contendo adr em pelo menos um átomo de carbono cabeça-de-ponte do grupo adamantil do referido composto farmacêutico contendo adamantano.
BR9801157A 1997-04-10 1998-04-08 Derivados de adamantano substituìdos por flúor. BR9801157A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4465897P 1997-04-10 1997-04-10

Publications (1)

Publication Number Publication Date
BR9801157A true BR9801157A (pt) 2000-03-21

Family

ID=21933590

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9801157A BR9801157A (pt) 1997-04-10 1998-04-08 Derivados de adamantano substituìdos por flúor.

Country Status (10)

Country Link
US (1) US6057364A (pt)
EP (1) EP0870757B1 (pt)
JP (2) JP2951313B2 (pt)
AT (1) ATE219044T1 (pt)
BR (1) BR9801157A (pt)
CA (1) CA2234319C (pt)
DE (1) DE69805909T2 (pt)
DK (1) DK0870757T3 (pt)
ES (1) ES2175614T3 (pt)
PT (1) PT870757E (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
JP2002040648A (ja) * 2000-07-28 2002-02-06 Sony Corp 露光方法
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US7795468B2 (en) * 2001-01-19 2010-09-14 Chevron U.S.A. Inc. Functionalized higher diamondoids
WO2005123653A1 (ja) * 2004-06-16 2005-12-29 Asahi Glass Company, Limited フルオロアダマンタン誘導体
JPWO2005123650A1 (ja) * 2004-06-16 2008-04-10 旭硝子株式会社 新規なフッ素化されたアダマンタン誘導体
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
RU2007140348A (ru) 2005-04-06 2009-05-20 Адамас Фармасьютикалс, Инк. (Us) Способы и композиции для лечения заболеваний цнс
MY145464A (en) * 2005-08-31 2012-02-15 Hoffmann La Roche Pyrazolone derivatives as 11-beta hsd1 inhibitors
JP5132238B2 (ja) * 2007-10-05 2013-01-30 国立大学法人北海道大学 フッ素化アダマンタン化合物の製造方法
TWI432188B (zh) * 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類
WO2010069595A1 (en) 2008-12-19 2010-06-24 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
CA2994873A1 (en) 2009-12-02 2011-06-09 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
CA2845854A1 (en) * 2011-08-19 2013-02-28 The Trustees Of Princeton University C-halogen bond formation
GB201206984D0 (en) * 2012-04-20 2012-06-06 Univ Manchester New therapeutic use
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
RU2616255C1 (ru) * 2016-05-16 2017-04-13 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) ПРИМЕНЕНИЕ (1S,3aR,4R,7aS)-N-(2,2,4,7a-ТЕТРАМЕТИЛОКТАГИДРО-1,4-ЭТАНОИНДЕН-3а-ИЛ)-АЦЕТАМИДА В КАЧЕСТВЕ ИНГИБИТОРА РЕПРОДУКЦИИ ВИРУСА ГРИППА
US11548893B2 (en) 2017-07-15 2023-01-10 Arisan Therapeutics Inc. Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2937211A (en) * 1958-10-17 1960-05-17 Du Pont Chemical process
US3352912A (en) * 1963-07-24 1967-11-14 Du Pont Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes
US3391142A (en) * 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
US4030994A (en) * 1971-06-18 1977-06-21 Merck & Co., Inc. Substitutive fluorination of organic compounds
GB1513135A (en) * 1974-06-04 1978-06-07 Res Inst For Med & Chem Inc Fluorination process and fluoro steroids
FR2514006A1 (fr) * 1981-10-05 1983-04-08 Nativelle Sa Ets Acylamino-4 aza-1 adamantanes, procede pour leur preparation, et application en therapeutique
ES8206435A1 (es) * 1981-10-29 1982-08-16 Especialidades Farmaco Terape Procedimiento para la obtencion de un nuevo compuesto deri- vado del acido p-clorofenoxiacetico
US4829086A (en) * 1984-03-14 1989-05-09 Bodor Nicholas S Soft β-adrenergic blocking agents
FR2572399B1 (fr) * 1984-10-31 1987-01-16 Panmedica Sa Nouveaux derives de l'adamantanamine, leurs procedes de preparation et medicaments les contenant
LU85849A1 (fr) * 1985-04-11 1986-11-05 Cird Derives benzonaphtaleniques,leur procede de preparation et leur application dans les domaines pharmaceutiques et cosmetiques
US5482940A (en) * 1988-05-24 1996-01-09 American Home Products Corporation Use of aryl- and heteroaryl piperazinyl carboxamides in the treatment of various central nervous system disorders
JP3136206B2 (ja) * 1991-10-22 2001-02-19 中外製薬株式会社 ベンゾジオキサン誘導体
US5854232A (en) * 1994-04-29 1998-12-29 Pfizer Inc. Acyclic anc cyclic amides as neurotransmitter release enhancers
US5599998A (en) * 1994-10-24 1997-02-04 Iowa State University Research Foundation, Inc. Method for the synthesis of adamantane amines

Also Published As

Publication number Publication date
DE69805909D1 (de) 2002-07-18
PT870757E (pt) 2002-09-30
JP2951313B2 (ja) 1999-09-20
ES2175614T3 (es) 2002-11-16
EP0870757A2 (en) 1998-10-14
ATE219044T1 (de) 2002-06-15
EP0870757B1 (en) 2002-06-12
CA2234319A1 (en) 1998-10-10
DE69805909T2 (de) 2002-09-26
CA2234319C (en) 2003-03-25
EP0870757A3 (en) 2000-06-07
US6057364A (en) 2000-05-02
DK0870757T3 (da) 2002-07-15
JPH10298135A (ja) 1998-11-10
JP3338400B2 (ja) 2002-10-28
JP2000026367A (ja) 2000-01-25

Similar Documents

Publication Publication Date Title
BR9801157A (pt) Derivados de adamantano substituìdos por flúor.
ATE185792T1 (de) Stilbenderivate und diese enthaltende pharmazeutische zusammensetzungen
CA2216796A1 (en) Quinazoline derivatives
NO306464B1 (no) Benzimidazolforbindelser, farmasöytiske preparater som omfatter slike forbindelser, samt anvendelse av forbindelsene for fremstilling av medikamenter
PT87542A (pt) Process for the preparation of a medicament based on indolone derivatives for the treatment of the parkinson disease
EA200200249A1 (ru) Производные 3(5)-уреидопиразола, способ их получения и их применение в качестве противоопухолевых агентов
ATE143806T1 (de) Verbesserungen von oder in bezug auf exzitatorische aminosäurenrezeptorantagonisten
ATE252082T1 (de) Isochinolderivate
KR950032171A (ko) 옥소피리디닐퀴녹살린 유도체
DE69823240D1 (de) Immunmodulierende arzneimittelzusammenstellung
DK0722724T3 (da) Anvendelse af L-carnitin og dets derivater til nedsættelse af de toksiske virkninger af cyclosporin-A og andre immunosuppre
ATE152708T1 (de) (1,2n) und (3,2n)-karbozyklische-2-amino- tetralinderivate
SE9702716D0 (sv) Substituted phenylazacycloalkanes in the treatment of cognitive disorders
MX9300638A (es) Derivados del acido aminobenzoico.
DE69635775D1 (de) Medikament gegen pulmonale herzprobleme
EP0813866A3 (en) Therapeutic agent for joint diseases
KR920017660A (ko) 의약품
PT1082116E (pt) Utilizacao de derivados de 4-piperidinometanol no tratamento de desordens do neurodesenvolvimento
DK0855398T3 (da) Sesquiterpenderivater med antiviral aktivitet
HUP0302255A2 (hu) Szulfonamidszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DE60213958D1 (de) Aryl-n-cyanoguanidine derivate und deren verwendung
PT889044E (pt) Derivados do 5-(heteroaril)alquil-3-oxo-pirido-(1,2-a)benzimidazole-4-carboxamida (pbi) uteis no tratamento de perturbacoes do sistema nervoso central
ATE197953T1 (de) Pyrrolo(4,3,2-de)chinolin-derivat
ES2141134T3 (es) Derivados de carbamoil pirrolidona para el tratamiento de la depresion y de los trastornos cerebrovasculares.
KR920002139A (ko) 뇌혈관 수축 치료제

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.